Isosteviol prevents the development of isoprenaline‑induced myocardial hypertrophy

Chen,Yaoxu; Beng,Huimin; Su,Hao; Han,Fuping; Fan,Zhuo; Lv,Nanying; Jovanović,Aleksandar; Tan,Wen

doi:10.3892/ijmm.2019.4342

Isosteviol prevents the development of isoprenaline‑induced myocardial hypertrophy

Authors:
- Yaoxu Chen
- Huimin Beng
- Hao Su
- Fuping Han
- Zhuo Fan
- Nanying Lv
- Aleksandar Jovanović
- Wen Tan
View Affiliations

Affiliations: Department of Innovative Drugs and Medicine, School of Bioscience and Bioengineering, South China University of Technology, Guangzhou, Guangdong 510641, P.R. China, Department of Basic and Clinical Sciences, University of Nicosia Medical School, CY‑1700 Nicosia, Cyprus
Published online on: September 17, 2019 https://doi.org/10.3892/ijmm.2019.4342
Pages: 1932-1942
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Isosteviol sodium (STVNa), which is a derivate of the natural sweet‑tasting glycoside stevioside, has recently been developed and it has been determined that this compound exhibits neuro‑ and cardio‑protective properties. In the current study, whether STVNa interferes with the development of cardiac hypertrophy, which is induced by isoprenaline (Iso), was investigated in an experimental rat model. Rats were treated with a vehicle (0.9% NaCl; control), isoprenaline (Iso; 5 mg/kg) or Iso (5 mg/kg) with STVNa (4 mg/kg; Iso + STVNa). Cardiomyocytes were isolated using enzymatic dissociation and were treated with 5 µM Iso for 24 h and co‑treated with 5 µM STVNa. Brain natriuretic peptide (BNP) mRNA expression was determined using PCR analysis. Cell surface area, intracellular reactive oxygen species (ROS), mitochondrial transmembrane potential (ΔΨm), cytoplasmic Ca2+ and Ca2+ and contractile function were examined using a laser scanning confocal microscope. The current study demonstrated that STVNa inhibited Iso‑induced cardiac hypertrophy by inhibiting cardiomyocyte size. STVNa significantly reduced cell surface area and decreased BNP mRNA expression in ventricular cardiomyocyte Iso‑induced hypertrophy. STVNa was also revealed to restore ΔΨm and reduce ROS generation and intracellular Ca2+ concentration when compared with the Iso‑treated group. Additionally, STVNa preserved Ca2+ transients in hypertrophic cardiomyocytes. In conclusion, the present study demonstrated that STVNa protects against Iso‑induced myocardial hypertrophy by reducing oxidative stress, restoring ΔΨm and maintaining Ca2+ homeostasis.

View Figures

View References

1	Hu H, Sun Xo, Tian F, Zhang H, Liu Q and Tan W: Neuroprotective effects of isosteviol sodium injection on acute focal cerebral ischemia in rats. Oxid Med Cell Longev. 2016.1379162:2016.
2	Zhang H, Sun X, Xie Y, Zan J and Tan W: Isosteviol sodium protects against permanent cerebral ischemia injury in mice via inhibition of NF-κB-mediated inflammatory and apoptotic responses. J Stroke Cerebrovasc Dis. 26:2603–2614. 2017. View Article : Google Scholar : PubMed/NCBI
3	Zan J, Zhang H, Lu MY, Beng HM, Zhong KL, Sun XO and Tan W: Isosteviol sodium injection improves outcomes by modulating TLRs/NF-κB-dependent inflammatory responses following experimental traumatic brain injury in rats. Neuroreport. 29:794–803. 2018. View Article : Google Scholar : PubMed/NCBI
4	Zhong KL, Lu MY, Liu F, Mei Y, Zhang XJ, Zhang H, Zan J, Sun XO and Tan W: Isosteviol sodium protects neural cells against hypoxia-induced apoptosis through inhibiting MAPK and NF-κB pathways. J Stroke Cerebrovasc Dis. 28:175–184. 2019. View Article : Google Scholar
5	Sun X, Yang Y, Xie Y, Shi X, Huang L and Tan W: Protective role of STVNa in myocardial ischemia reperfusion injury by inhibiting mitochondrial fission. Oncotarget. 9:1898–1905. 2017.
6	Liu Q, Hu H, Hu T, Han T, Wang A, Huang L, Tan Q and Tan W: STVNa attenuates right ventricle hypertrophy and pulmonary artery remodeling in rats induced by transverse aortic constriction. Biomed Pharmacother. 101:371–378. 2018. View Article : Google Scholar : PubMed/NCBI
7	Tang SG, Liu XY, Ye JM, Hu TT, Yang YY, Han T and Tan W: Isosteviol ameliorates diabetic cardiomyopathy in rats by inhibiting ERK and NF-κB signaling pathways. J Endocrinol. 238:47–60. 2018. View Article : Google Scholar : PubMed/NCBI
8	Dini FL, Galeotti GG, Terlizzese G, Fabiani I, Pugliese NR and Rovai I: Left ventricular mass and thickness: Why does it matter? . Heart Fail Clin. 15:159–166. 2019. View Article : Google Scholar : PubMed/NCBI
9	Bertero E and Maack C: Metabolic remodelling in heart failure Nat Rev Cardiol. 15:457–470. 2018.
10	Haselhuhn LR, Brotman DJ and Wittstein IS: Heart failure guidelines: What you need to know about the 2017 focused update. Cleve Clin J Med. 86:123–139. 2019. View Article : Google Scholar : PubMed/NCBI
11	Tse J, Powell JR, Baste CA, Priest RE and Kuo JF: Isoproterenol-induced cardiac hypertrophy: Modifications in characteristics of beta-adrenergic receptor, adenylate cyclase, and ventricular contraction. Endocrinology. 105:246–255. 1979. View Article : Google Scholar : PubMed/NCBI
12	Morisco C, Zebrowski DC, Vatner DE, Vatner SF and Sadoshim J: Beta-adrenergic cardiac hypertrophy is mediated primarily by the beta(1)-subtype in the rat heart. J Mol Cell Cardiol. 33:561–573. 2001. View Article : Google Scholar : PubMed/NCBI
13	Osadchii OE: Cardiac hypertrophy induced by sustained beta-adrenoreceptor activation: Pathophysiological aspects. Heart Fail Rev. 12:66–86. 2007. View Article : Google Scholar : PubMed/NCBI
14	Nichtova Z, Novotova M, Kralova E and Stankovicova T: Morphological and functional characteristics of models of experimental myocardial injury induced by isoproterenol. Gen Physiol Biophys. 31:141–151. 2012. View Article : Google Scholar : PubMed/NCBI
15	Krenek P, Kmecova J, Kucerova D, Bajuszova Z, Musil P, Gazova A, Ochodnicky P, Klimas J and Kyselovic J: Isoproterenol-induced heart failure in the rat is associated with nitric oxide-dependent functional alterations of cardiac function. Eur J Heart Fail. 11:140–146. 2009. View Article : Google Scholar : PubMed/NCBI
16	Claycomb WC and Palazzo MC: Culture of the terminally differentiated adult cardiac muscle cell: A light and scanning electron microscope study. Dev Biol. 80:466–482. 1980. View Article : Google Scholar : PubMed/NCBI
17	Sergeeva IA and Christoffels VM: Regulation of expression of atrial and brain natriuretic peptide, biomarkers for heart development and disease. Biochem Biophys Acta. 1832.2403–2412. 2013.
18	Shin E, Ko KS, Rhee BD, Han J and Kim N: Different effects of prolonged β-adrenergic stimulation on heart and cerebral artery. Integr Med Res. 3:204–210. 2014. View Article : Google Scholar : PubMed/NCBI
19	Zhang GX, Kimura S, Nishiyama A, Shokoji T, Rahman M, Yao L, Nagai Y, Fujisawa Y, Miyatake A and Abe Y: Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. Cardiovasc Res. 65:230–238. 2005. View Article : Google Scholar
20	Srivastava S, Chandrasekar B, Gu Y, Luo J, Hamid T, Hill BG and Prabhu SD: Downregulation of cuzn-superoxide dismutase contributes to beta-adrenergic receptor-mediated oxidative stress in the heart. Cardiovasc Res. 74:445–455. 2007. View Article : Google Scholar : PubMed/NCBI
21	Takimoto E and Kass DA: Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension. 49:241–248. 2007. View Article : Google Scholar
22	Vidal M, Wieland T, Lohse MJ and Lorenz K: β-Adrenergic receptor stimulation causes cardiac hypertrophy via a Gβγ/Erk-dependent pathway. Cardiovasc Res. 96:255–264. 2012. View Article : Google Scholar : PubMed/NCBI
23	Cha HN, Choi JH, Kim YW, Kim JY, Ahn MW and Park SY: Metformin inhibits isoproterenol-induced cardiac hypertrophy in mice. Korean J Physiol Pharmacol. 14:377–384. 2010. View Article : Google Scholar
24	Murphy MP: How mitochondria produce reactive oxygen species. Biochem J. 417:1–13. 2009. View Article : Google Scholar
25	Jovanović A: Cardioprotective signaling: Past, present and future. Eur J Pharmacol. 833:314–319. 2018. View Article : Google Scholar
26	Zhou B, Wu LJ, Li LH, Tashiro S, Onodera S, Uchiumi F and Ikejima T: Silibinin protects against isoproterenol-induced rat cardiac myocyte injury through mitochondrial pathway after up-regulation of sirt1. J Pharmacol Sci. 102:387–395. 2006. View Article : Google Scholar : PubMed/NCBI
27	Zhang Y, Xu J, Long Z, Wang C, Wang L, Sun P, Li P and Wang T: Hydrogen (H₂) inhibits isoproterenol-induced cardiac hypertrophy via antioxidative pathways. Front Pharmacol. 7:3922016.
28	Remondino A, Kwon SH, Communal C, Pimentel DR, Sawyer DB, Singh K and Colucci WS: Beta-Adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2-terminal kinase-dependent activation of the mitochondrial pathway. Circ Res. 92:136–138. 2003. View Article : Google Scholar : PubMed/NCBI
29	Eisner DA, Caldwell JL, Kistamás K and Trafford AW: Calcium and excitation-contraction coupling in the heart. Circ Res. 121:181–195. 2017. View Article : Google Scholar : PubMed/NCBI
30	Du Q, Jovanović S, Clelland A, Sukhodub A, Budas G, Phelan K, Murray-Tait V, Malone L and Jovanović A: Overexpression of SUR2A generates a cardiac phenotype resistant to ischaemia. FASEB J. 20:1131–1141. 2006. View Article : Google Scholar : PubMed/NCBI
31	Sukhodub A, Sudhir R, Du Q, Jovanović S, Reyes S and Jovanović A: Nicotinamide-rich diet improves physical endurance by up-regulating SUR2A in the heart. J Cell Mol Med. 15:1703–1712. 2011. View Article : Google Scholar
32	de Lucia C, Eguchi A and Koch WJ: New insights in cardiac β-adrenergic signaling during heart failure and aging. Front Pharmacol. 9:9042018. View Article : Google Scholar
33	Rengo G, Lymperopoulos A and Koch WJ: Future g protein-coupled receptor targets for treatment of heart failure. Curr Treat Options Cardiovasc Med. 11:328–338. 2009. View Article : Google Scholar : PubMed/NCBI
34	Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S, et al: Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: Coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor downregulation in heart failure. Circ Res. 59:297–309. 1986. View Article : Google Scholar : PubMed/NCBI
35	Dorn GW II and Force T: Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest. 115:527–537. 2005. View Article : Google Scholar : PubMed/NCBI
36	Bertero E and Maack C: Calcium signaling and reactive oxygen species in mitochondria. Circ Res. 122:1460–1478. 2018. View Article : Google Scholar : PubMed/NCBI
37	Fan Z, Wen T, Chen Y, Huang L, Lin W, Yin C and Tan W: Isosteviol sensitizes sarcKATP channels towards pinacidil and potentiates mitochondrial uncoupling of diazoxide in Guinea Pig ventricular myocytes. Oxid Med Cell Longev. 2016.6362812:2016.
38	Jovanović S, Du Q, Sukhodub A and Jovanović A: M-LDH physically associated with sarcolemmal K channels mediates cytoprotection in heart embryonic H9C2 cells. Int J ATP Biochem Cell Biol. 41:2295–2301. 2009. View Article : Google Scholar
39	Jovanović S, Du Q, Sukhodub A and Jovanović A: Dual mechanism of cytoprotection afforded by M-LDH in embryonic heart H9C2 cells. Biochim Biophys Acta. 1793:1379–1386. 2009. View Article : Google Scholar